Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator

被引:33
作者
Mohanam, S
Chandrasekar, N
Yanamandra, N
Khawar, S
Mirza, F
Dinh, DH
Olivero, WC
Rao, JS
机构
[1] Univ Illinois, Coll Med, Div Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA
[2] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA
关键词
ATF; uPA; glioblastoma; invasiveness;
D O I
10.1038/sj.onc.1205893
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The binding of urokinase-type plasminogen activator (uPA) to its receptor (uPAR) on the surface of tumor cells is involved in the activation of proteolytic cascades responsible for the invasiveness of those cells. The diffuse, extensive infiltration of glioblastomas into the surrounding normal brain tissue is believed to rely on modifications of the proteolysis of extracellular matrix components; blocking the interaction between uPA and uPAR might be a suitable approach for inhibiting glioma tumorigenesis. We assessed how expression of an amino-terminal fragment (ATF) of uPA that contains binding site to uPAR affects the invasiveness of SNB19 human glioblastoma cells. SNB19 cells were transfected with an expression plasmid (pcDNA3-ATF) containing a cDNA sequence of ATF-uPA. The resulting ATF-uPA-expressing clones showed markedly less cell adhesion, spreading, and clonogenicity than did control cells. Endogenous ATF expression also significantly decreased the invasive capacity of transfected glioblastoma cells in Matrigel and spheroid-rat brain cell aggregate models. ATF-uPA transfectants were also markedly less invasive than parental SNB19 cells after injection into the brains of nude mice, suggesting that competitive inhibition of the uPA-uPAR interaction on SNB19 cells by means of transfection with ATF cDNA could be a useful therapeutic strategy for inhibiting tumor progression.
引用
收藏
页码:7824 / 7830
页数:7
相关论文
共 27 条
[1]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[2]  
2-Z
[3]   Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides [J].
Burgle, M ;
Koppitz, M ;
Riemer, C ;
Kessler, H ;
Konig, B ;
Weidle, UH ;
Kellermann, J ;
Lottspeich, F ;
Graeff, H ;
Schmitt, M ;
Goretzki, L ;
Reuning, U ;
Wilhelm, O ;
Magdolen, V .
BIOLOGICAL CHEMISTRY, 1997, 378 (3-4) :231-237
[4]   PREVENTION OF METASTASIS BY INHIBITION OF THE UROKINASE RECEPTOR [J].
CROWLEY, CW ;
COHEN, RL ;
LUCAS, BK ;
LIU, GH ;
SHUMAN, MA ;
LEVINSON, AD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (11) :5021-5025
[5]   The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule [J].
Dear, AE ;
Medcalf, RL .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1998, 252 (02) :185-193
[6]  
Duffy MJ, 1996, CLIN CANCER RES, V2, P613
[7]   Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells [J].
Festuccia, C ;
Dolo, V ;
Guerra, F ;
Violini, S ;
Muzi, P ;
Pavan, A ;
Bologna, M .
CLINICAL & EXPERIMENTAL METASTASIS, 1998, 16 (06) :513-528
[8]   Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors [J].
Go, Y ;
Chintala, SK ;
Mohanam, S ;
Gokaslan, Z ;
Venkaiah, B ;
Bjerkvig, R ;
Oka, K ;
Nicolson, GL ;
Sawaya, R ;
Rao, JS .
CLINICAL & EXPERIMENTAL METASTASIS, 1997, 15 (04) :440-446
[9]   INHIBITION OF METASTASIS OF LEWIS LUNG-CARCINOMA BY A SYNTHETIC PEPTIDE WITHIN GROWTH FACTOR-LIKE DOMAIN OF UROKINASE IN THE EXPERIMENTAL AND SPONTANEOUS METASTASIS MODEL [J].
KOBAYASHI, H ;
GOTOH, J ;
FUJIE, M ;
SHINOHARA, H ;
MONIWA, N ;
TERAO, T .
INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (05) :727-733
[10]   Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87) [J].
Krüger, A ;
Soeltl, R ;
Lutz, V ;
Wilhelm, OG ;
Magdolen, V ;
Rojo, EE ;
Hantzopoulos, PA ;
Graeff, H ;
Gänsbacher, B ;
Schmitt, M .
CANCER GENE THERAPY, 2000, 7 (02) :292-299